- Email: [email protected]
4871660 Luminescence immuno-test kits, method for stabilizing same and quality control thereof
New Patents
4871540 PROCESS FOR PRODUCING A BIOLOGICALLY ACTIVE SUBSTANCE AND COMPOSITIONS CONTAINING THE SAME Yasuhiko Kojima, Sadao Tamamura, Totsuka ku, Yokohama shi, Kanagawa ken, Japan assigned to Kojima Yasuhiko A biologically active substance comprising a kind of glycolipid having an elemental analysis (~,~,) of H: 5.20-5.40, C: 42.55-44.17 and N: 3.944.08 and a molecular weight of about 30,000-106 is obtained by extracting the tissue of a plant of maize (Zea mays Linne) or a variant thereof by extracting the tissue with water and recovering the desired active substance from the resultant extract. This substance is capable of inhibiting the formation of IgE antibodies and promoting the formation of IgG and lgM antibodies, and moreover exhibits various biological activities such as interferon-inducing activity, polyclonal B lymphocite activating activity, mitrogenic activity, adjuvant activity and anti-tumour activity. Thus, this substance is expected to be useful for preventing and treating, for example, aesthema, rhintitis, B-type hepatitis, AIDS and other allergic diseases and immunological insufficiency.
4871659 REAGENT FOR DETECTING NON-A, NON-B VIRAL HEPATITIS (NANBH) AND AN IMMUNOENZYMATIC METHOD FOR DETECTING NANBH ANTIGENS IN FECAL EXTRACTS
isolating an antibody of this type is provided. A reagent for detecting epidemic NANB hepatitis comprises the anti-NANBH IgM fixed to a solid support. The reagent is useful for diagnosing epidemic N A N B viral hepatitis by forming an immunological complex between the antiN A N B H IgM and antigen in a fecal extract from a patient being diagnosed, and then incubating the immunological complex with enzymelabeled IgG from serum of a human convalescing from epidemic NANBH. The complex is detected by developing the enzyme.
4871660 LUMINESCENCE IMMUNO-TEST KITS, METHOD FOR STABILIZING SAME AND QUALITY CONTROL THEREOF Andre Gadow, Berlin, Federal Republic Of Germany assigned to Henning Berlin GmbH Luminescence immuno-test kits consist of an antigen or antibody capable of showing luminescence and labelled with phthalic hydrazides, an antibody or antigen preferably bound to a carrier and an oxidizing reagent inducing the luminescence to occur and are characterized in that the oxidizing reagent is a pre-fabricated solution of catalase, optionally stabilized by a bacteriostat, and the initiator is a pre-fabricated peroxide solution which is at least 20 minutes old. These luminescence immuno-tests are particularly stable and may be subjected to a quality control in a simple and inexpensive way.
4871834 MONOCLONAL SPECIFIC
ANTIBODIES TO CEA
Jacques Pillot, Gif Sur Yvette, France assigned to Institut Pasteur
Yuji Matsuoka, Masahide Kuroki, Sawara ku, Fukuoka shi, Fukuoka ken, Japan
A n t i - N A N B H (anti-non-A, non-B hepatitis) antibody comprises IgM isolated from sera of monkeys artificially infected with extracts of feces from patients known to be suffering from epidemic N A N B hepatitis. A process for
A process for producing monoclonal antibodies specific to carcinoembryonic antigen (CEA), comprising immunizing a mammal with a first CEA to produce cells capable of producing antibodies, collecting the cells from the mammal,
4871540 PROCESS FOR PRODUCING A BIOLOGICALLY ACTIVE SUBSTANCE AND COMPOSITIONS CONTAINING THE SAME Yasuhiko Kojima, Sadao Tamamura, Totsuka ku, Yokohama shi, Kanagawa ken, Japan assigned to Kojima Yasuhiko A biologically active substance comprising a kind of glycolipid having an elemental analysis (~,~,) of H: 5.20-5.40, C: 42.55-44.17 and N: 3.944.08 and a molecular weight of about 30,000-106 is obtained by extracting the tissue of a plant of maize (Zea mays Linne) or a variant thereof by extracting the tissue with water and recovering the desired active substance from the resultant extract. This substance is capable of inhibiting the formation of IgE antibodies and promoting the formation of IgG and lgM antibodies, and moreover exhibits various biological activities such as interferon-inducing activity, polyclonal B lymphocite activating activity, mitrogenic activity, adjuvant activity and anti-tumour activity. Thus, this substance is expected to be useful for preventing and treating, for example, aesthema, rhintitis, B-type hepatitis, AIDS and other allergic diseases and immunological insufficiency.
4871659 REAGENT FOR DETECTING NON-A, NON-B VIRAL HEPATITIS (NANBH) AND AN IMMUNOENZYMATIC METHOD FOR DETECTING NANBH ANTIGENS IN FECAL EXTRACTS
isolating an antibody of this type is provided. A reagent for detecting epidemic NANB hepatitis comprises the anti-NANBH IgM fixed to a solid support. The reagent is useful for diagnosing epidemic N A N B viral hepatitis by forming an immunological complex between the antiN A N B H IgM and antigen in a fecal extract from a patient being diagnosed, and then incubating the immunological complex with enzymelabeled IgG from serum of a human convalescing from epidemic NANBH. The complex is detected by developing the enzyme.
4871660 LUMINESCENCE IMMUNO-TEST KITS, METHOD FOR STABILIZING SAME AND QUALITY CONTROL THEREOF Andre Gadow, Berlin, Federal Republic Of Germany assigned to Henning Berlin GmbH Luminescence immuno-test kits consist of an antigen or antibody capable of showing luminescence and labelled with phthalic hydrazides, an antibody or antigen preferably bound to a carrier and an oxidizing reagent inducing the luminescence to occur and are characterized in that the oxidizing reagent is a pre-fabricated solution of catalase, optionally stabilized by a bacteriostat, and the initiator is a pre-fabricated peroxide solution which is at least 20 minutes old. These luminescence immuno-tests are particularly stable and may be subjected to a quality control in a simple and inexpensive way.
4871834 MONOCLONAL SPECIFIC
ANTIBODIES TO CEA
Jacques Pillot, Gif Sur Yvette, France assigned to Institut Pasteur
Yuji Matsuoka, Masahide Kuroki, Sawara ku, Fukuoka shi, Fukuoka ken, Japan
A n t i - N A N B H (anti-non-A, non-B hepatitis) antibody comprises IgM isolated from sera of monkeys artificially infected with extracts of feces from patients known to be suffering from epidemic N A N B hepatitis. A process for
A process for producing monoclonal antibodies specific to carcinoembryonic antigen (CEA), comprising immunizing a mammal with a first CEA to produce cells capable of producing antibodies, collecting the cells from the mammal,